Ed Harrigan

Insider profile

Currently holds positions in Acadia Pharmaceuticals Inc., PhaseBio Pharmaceuticals Inc and Incyte Corp

Performance

Overall performance
0.8
Performance over holding periods
0.8
30 days 90 days 120 days
Average return -9% 8.2% 15.1%
Success rate 0% 68% 82%
Transactions
1 100% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Independent Director Acadia Pharmaceuticals Inc. Nov. 30, 2015 -
Independent Director PhaseBio Pharmaceuticals Inc Dec. 31, 2018 -
Independent Director Incyte Corp Dec. 16, 2019 -
Independent Director Bellicum Pharmaceuticals Inc Feb. 23, 2018 - Dec. 19, 2019
Ed Harrigan's trades of PhaseBio Pharmaceuticals Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Planned sale
Price
68.28
Quantity 55,659 -9.4%
Value US$3,489,797
Transaction date
Planned sale
Price
118.72
Quantity 31,453 +7.4%
Value US$3,121,336
Transaction date
Planned sale
Price
91.79
Quantity 30,000 -28.5%
Value US$2,753,700
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2020-12-04 2020-12-03
B Purchase
91,201 -41.1%
183.84
US$4,290,017 		91,201 -41.1% 183.84 US$4,290,017
2020-08-14 2020-08-12
PlS Planned sale
55,659 -9.4%
68.28
US$3,489,797 		55,659 -9.4% 68.28 US$3,489,797
2020-07-13 2020-07-13
PlS Planned sale
31,453 +7.4%
118.72
US$3,121,336 		31,453 +7.4% 118.72 US$3,121,336
2020-06-15 2020-06-12
PlS Planned sale
30,000 -28.5%
91.79
US$2,753,700 		30,000 -28.5% 91.79 US$2,753,700